Mglur1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
This page provides comprehensive information about this protein. See the content below for detailed information.
The mGluR1 protein is a class C G-protein coupled receptor consisting of three main domains:
mGluR1 is a Group I metabotropic glutamate receptor that couples to Gq proteins and activates phospholipase C signaling. It plays critical roles in synaptic plasticity, learning, and memory.
The metabotropic glutamate receptors transduce signals through G-proteins:
Alzheimer's Disease: Dysregulated mGluR signaling contributes to:
Parkinson's Disease: Target for therapeutic intervention in:
Other Disorders: Schizophrenia, epilepsy, anxiety, Fragile X syndrome
Positive Allosteric Modulators (PAMs)
Negative Allosteric Modulators (NAMs)
Conn PJ, et al. "Metabotropic glutamate receptors: physiology, pharmacology, and disease." Annu Rev Pharmacol Toxicol. 2022. DOI: 10.1146/annurev-pharmtox-052120-013257
Niswender CM, Conn PJ. "Metabotropic glutamate receptors: therapeutic targets for neurodegenerative disorders." Neuropharmacology. 2023. DOI: 10.1016/j.neuropharm.2022.109256
Dorostkar MM, et al. "Metabotropic glutamate receptor modulation in Alzheimer's disease." Alzheimers Res Ther. 2021. DOI: 10.1186/s13195-021-00876-5
The study of Mglur1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Conn PJ, et al. "Metabotropic glutamate receptors: physiology, pharmacology, and disease." Annu Rev Pharmacol Toxicol. 2022;62:283-323. DOI:10.1146/annurev-pharmtox-052120-013257
Niswender CM, Conn PJ. "Metabotropic glutamate receptors: therapeutic targets for neurodegenerative disorders." Neuropharmacology. 2023;212:109256. DOI:10.1016/j.neuropharm.2022.109256
Dorostkar MM, et al. "Metabotropic glutamate receptor modulation in Alzheimer's disease." Alzheimers Res Ther. 2021;13(1):176. DOI:10.1186/s13195-021-00876-5
Ferraguti F, et al. "Metabotropic glutamate receptors." Cell Tissue Res. 2022;390(1):1-40. DOI:10.1007/s00441-022-03641-w
Bhattacharya S, et al. "Structural basis of metabotropic glutamate receptor signaling." Neuropharmacology. 2021;195:108376. DOI:10.1016/j.neuropharm.2021.108376
Gregory KJ, et al. "Metabotropic glutamate receptor allosteric modulators as drug candidates." Neurotherapeutics. 2022;19(3):902-920. DOI:10.1007/s13311-022-01226-3
Emmitte KA. "mGluR1 negative allosteric modulators: a patent review (2015-2022)." Expert Opin Ther Pat. 2023;33(1):13-27. DOI:10.1080/13543776.2023.2167896
Wang H, et al. "mGluR1 in neurological disorders." J Neurochem. 2024;168(2):234-251. DOI:10.1111/jnc.15989